• Image courtesy of Dr Kristen Brennand & Dr Fred H. Gage/ Salk Institute for Biological Studies

    human stem cells 2
  • Image courtesy of Dr Yichen Shi and Dr Rick Livesey/ Cambridge Stem Cell Institute

    human stem cells
About EUCelLEX

The European EUCelLEX Project consists in a full examination of the application of the European rules regarding cell banks together with current practices in respect of the therapeutic use of human cells in the different countries concerned. The purpose is to submit the data obtained to the European Commission for it to draw up legislative measures in line with medical advances in this field.
The EUCelLEX project has received funding from the European Union’s FP7 and is coordinated by Emmanuelle RIAL-SEBBAG (Inserm).

Home

News

The European Medicines Agency (EMA) published a report from a multi-stakeholder expert meeting held on 27 May 2016 to explore possible ways to foster the development of ATMPs in Europe and expand patients’ access to these new treatments.

To view the press release click here.

To view the PDF click here.

The detailed Preliminary Programme of the EUCelLEX Final Conference is now available here.

Reminder : this conference will be held in Paris on September 22-23, in the Institut Curie, amphithéâtre BDD (1 rue Pierre & Marie Curie – Paris 75005).

Online Registration here.

Further information here.

Author: Megan Scudellari

Article in Nature,  534, 310–312 (16 June 2016) doi:10.1038/534310a

Induced pluripotent stem cells were supposed to herald a medical revolution. But ten years after their discovery, they are transforming biological research instead.

View full text

Author: Sara Reardon

Article in Nature doi:10.1038/nature.2016.20137

CRISPR, the genome-editing technology that has taken biomedical science by storm, is finally nearing human trials.

On 21 June, an advisory committee at the US National Institutes of Health (NIH) approved a proposal to use CRISPR–Cas9 to help augment cancer therapies that rely on enlisting a patient’s T cells, a type of immune cell.

This first trial is small and designed to test whether CRISPR is safe for use in people, rather than whether it effectively treats cancer or not. It will be funded by a US$250-million immunotherapy foundation formed in April by former Facebook president Sean Parker. The trial itself does not yet have a budget. The University of Pennsylvania will manufacture the edited cells, and will recruit and treat patients alongside centres in California and Texas.

View full text

Authors : Timothy Caulfield, Douglas Sipp, Charles E. Murry, George Q. Daley, Jonathan Kimmelman.

Article in : Science 13 May 2016: Vol. 352, Issue 6287, pp. 776-777. DOI: 10.1126/science.aaf4620.

Summary
The way science is represented to the public can influence understanding and expectations, frame policy debates, and affect the implementation and use of emerging technologies. Inaccurate representations of research may, for example, lead to public confusion about the readiness of a technology for clinical application. As a result, the issue of science “hype”—in which the state of scientific progress, the degree of certainty in models or bench results, or the potential applications of research are exaggerated—is receiving increased attention from the popular press, the research community, and scientific societies. In newly issued guidelines on the ethical conduct of human pluripotent stem cell research and clinical translation, the International Society for Stem Cell Research (ISSCR) explicitly recognizes and confronts the issue of science hype. By placing a clear obligation on researchers, the ISSCR hopes to make balance in public representations of research a norm associated with scientific integrity. The focus on public communication, which is new to this version of the guidelines, is the result of both specific concerns regarding how stem cell research has been portrayed in the public sphere and the growing recognition that researchers play an important role in the science communication process.

View full text.